ArticleVeterinary ophthalmology2026
Outcomes of 39 Canine Eyes Treated With Combined Endoscopic Cyclophotocoagulation and Ahmed Valve Gonioimplantation for Glaucoma.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the long-term (> 1 year) outcomes of vision and intraocular pressure (IOP) control in dogs with glaucoma undergoing combined endoscopic cyclophotocoagulation (ECP) and Ahmed valve gonioimplantation (AVG).
methodsMedical records between 2020 and 2025 were reviewed. Outcomes evaluated included IOP control (< 25 mmHg), vision preservation, number of medications, and complications. A successful outcome was defined as intact menace response and controlled IOP < 25 mmHg.
resultsMedian (range) follow-up time for 39 eyes (32 dogs) was 26 (12-65) months. Among eyes with documented vision status at each postoperative time point, vision was preserved in 72.0% (18/25) at 12 months, 72.2% (13/18) at 18 months, 75% (12/16) at 24 months, 57.1% (4/7) at 30 months, and 69.2% (9/13) at 36 months. Among eyes with IOP recorded at each postoperative time point, IOP was controlled in 96.9% (31/32) at 12 months, 95.7% (22/23) at 18 months, and 100% at 24 months (19/19), 30 months (11/11), and 36 months (9/9). These outcomes were achieved with antiglaucoma medications administered when clinically indicated; however, medication burden decreased from a median of 3 preoperatively to 1 at 36 months postoperatively. Common complications included IOP spikes (n = 18/39 eyes, 46.2%), intraocular fibrin (n = 9/39 eyes, 23.1%), corneal ulceration (n = 9/39 eyes, 23.1%), uveitis (n = 8/39 eyes, 20.5%), and corneal edema (n = 7/39 eyes, 17.9%).
conclusionsThe combined ECP/AVG approach was successful in maintaining vision and controlling IOP for more than 1 year in the patients included. Outcomes were similar between glaucoma types, while preoperative vision status was significantly associated with postoperative visual outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.